Angiogenesis imaging using 68Ga-RGD PET: Preliminary report from Seoul National University Hospital

Current Medical Imaging Reviews

Volumn 6, Issue 1, 2010, Pages 56-59

  Lee, Ho Young ^a   Kang, Keon Wook ^a,b   Kim, Tae You ^a,b   Lee, Yun Sang ^a   Jeong, Jae Min ^a,b   Han, Sae Won ^a   Paeng, Jin Chul ^a   Chung, June Key ^a,b   Lee, Myung Chul ^a   Lee, Dong Soo ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Angiogenesis; FDG; Positron emission tomography; RGD

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; BEVACIZUMAB; FLUORODEOXYGLUCOSE F 18; GALLIUM 68;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; DRUG HALF LIFE; DRUG UPTAKE; HUMAN; POSITRON EMISSION TOMOGRAPHY; PREDICTOR VARIABLE; PRIORITY JOURNAL; REVIEW; SOUTH KOREA; TREATMENT RESPONSE; UNIVERSITY HOSPITAL;

EID: 77950221435     PISSN: 15734056     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340510790694009     Document Type: Review

References (29)

1. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-286
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257
3. Folkman K. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186
4. Rimassa L, Santoro A. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther 2009; 9: 739-745
5. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124
6. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha V beta 3 for angiogenesis. Science 1994; 264: 569-571
7. Jiang HJ, Zhang ZR, Shen BZ, et al. Functional CT for assessment of early vascular physiology in liver tumors. Hepatobiliary Pancreat Dis Int 2008; 7: 497-502.
8. Turkbey B, Kobayashi H, Ogawa M, et al. Imaging of tumor angiogenesis: functional or targeted? Am J Roentgenol 2009; 193: 304-313
9. Chen X, Sieverse E, Hou Y, et al. Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia 2005; 7: 271-279
10. Dijkgraaf I, Beer AJ, Wester HJ. Application of RGD-containing peptides as imaging probes for alphaVbes3 expression. Front Biosci 2009; 1: 887-899
11. Cai W, Niu G, Chen X. Imaging of integrins as biomarkers for tumor angiogensis. Curr Pharms Des 2003; 90: 577-585
12. Hamano Y, Zeisberg M, Sugimoto H, et al. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alpha v beta3 integrin. Cancer Cell 2003; 3: 589-601.
13. Bafetti LM, Young TN, Itoh Y, Stack MS. Intact vitronectin induces matrix metalloproteinase-2 and tissue inhibitor of metalloproteinases-2 expression and enhanced cellular invasion by melanoma cells. J Biol Chem 1998; 27: 143-149
14. Seftor RE, Seftor EA, Gehlsen KR, et al. Role of the alpha v beta 3 integrin in human melanoma cell invasion. Proc Natl Acad Sci USA 1992; 89: 1557-1561
15. 68Ga-labeled c(RGDyK)- isothiocyanatobenzyl-1, 4,7-triazacyclononane 1,4,7-triacetic acid and feasibility studies in mice. J Nucl Med 2008; 49: 830-836
16. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semi Nucl Med 2006; 36: 228-247
17. 68Ga in dilute HCl. Int J Appl radiation Isot 1981; 32: 31-36
18. 68Ga for medial application. J Nucl Med 2007; 48: 1741-1748
19. 68Ga and investigation of In vitro properties. Nucl Med Mol Imaging 2009; 43: 330-336
20. Beer AJ, Haubner R, Wolf I, et al. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. J Nucl Med 2006; 47: 763-769
21. Smith JW, Cheresh DA. Integrin (alpha v beta 3)-ligand interaction. Identification of a heterodimeric RGD binding site on the vitronectin receptor. J Biol Chem 1990; 265: 2168-2172
22. Haubner R, Decristoforo C. Radiolabelled RGD peptides and peptidomimetics for tumour targeting. Front Biosci 2009; 14: 872-886
23. Haubner R, Kuhnast B, Mang C, et al. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 2004; 15: 61-69
24. Beer AJ, Haubner R, Goebel M, et al. Biodistribution and pharmacokinetics of the alphaVbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med 2005; 46 1333-1341
25. Beer AJ, Haubner R, Wolf I, et al. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha V beta3 expression. J Nucl Med 2006; 47: 763-769
26. Beer AJ, Haubner R, Sarbia M, et al. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 2006; 12: 3942-3949
27. Beer AJ, Lorenzen S, Metz S, et al. Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med 2008; 49: 22-29
28. Li ZB, Cai W, Cao Q, et al. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med 2007; 48: 1162-1171
29. Li ZB, Chen K, Chen X. (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression. Eur J Nucl Med Mol Imaging 2008; 35(6): 1100-1108